Evotec (NASDAQ:EVO) Sees Strong Trading Volume – What’s Next?

Evotec SE (NASDAQ:EVO) shares saw an uptick in trading volume on Thursday . 352,319 shares traded hands during trading, an increase of 151% from the previous session’s volume of 140,616 shares.The stock last traded at $3.68 and had previously closed at $3.27.

Evotec Stock Performance

The business has a fifty day moving average price of $3.73 and a 200 day moving average price of $4.06. The company has a quick ratio of 1.99, a current ratio of 2.09 and a debt-to-equity ratio of 0.43.

Institutional Investors Weigh In On Evotec

A number of large investors have recently added to or reduced their stakes in EVO. CSS LLC IL acquired a new stake in Evotec during the 4th quarter worth approximately $50,000. Lighthouse Investment Partners LLC acquired a new stake in shares of Evotec in the fourth quarter valued at approximately $166,000. Bank of America Corp DE grew its position in Evotec by 262.5% during the fourth quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock worth $53,000 after buying an additional 9,289 shares in the last quarter. BNP Paribas Financial Markets acquired a new position in Evotec in the 4th quarter valued at $27,000. Finally, DCF Advisers LLC grew its holdings in shares of Evotec by 5.9% during the 4th quarter. DCF Advisers LLC now owns 229,871 shares of the company’s stock worth $956,000 after purchasing an additional 12,816 shares in the last quarter. Institutional investors own 5.81% of the company’s stock.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health.